Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

Published Date: 26 Aug 2024

In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds primary-care doctors often overlook prostate cancer risk in Black men

2.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

3.

FDA Approves New Drug Combo for RR Multiple Myeloma

4.

Year in Review: Chronic Lymphocytic Leukemia

5.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot